Hoth Therapeutics
(NASDAQ:HOTH)
$1.49
0.11[7.97%]
At close: Mar 28
$1.49
0[0.00%]
PreMarket: 6:03AM EDT
Consensus Rating1
Buy
Highest Price Target1
$14.00
Lowest Price Target1
$4.00
Consensus Price Target1
$7.63

Hoth Therapeutics Stock (NASDAQ:HOTH), Analyst Ratings, Price Targets, Predictions

Hoth Therapeutics Inc has a consensus price target of $7.63, established from looking at the 10 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., EF Hutton, and EF Hutton on February 5, 2024, September 14, 2023, and August 23, 2023. With an average price target of $8.5 between HC Wainwright & Co., EF Hutton, and EF Hutton, there's an implied 470.47% upside for Hoth Therapeutics Inc from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Feb
1
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
EF Hutton
Benchmark
EF Hutton

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Hoth Therapeutics

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
02/05/2024HOTHBuy Now
Hoth Therapeutics
$1.49168.46%HC Wainwright & Co.
Raghuram Selvaraju
→ $4Initiates → BuyGet Alert
09/14/2023HOTHBuy Now
Hoth Therapeutics
$1.49403.36%EF Hutton
Elemer Piros
$12 → $7.5MaintainsBuyGet Alert
08/23/2023HOTHBuy Now
Hoth Therapeutics
$1.49839.6%EF Hutton
Elemer Piros
→ $14Assumes → BuyGet Alert
06/20/2023HOTHBuy Now
Hoth Therapeutics
$1.49235.57%Benchmark
Bruce Jackson
→ $5ReiteratesSpeculative Buy → Speculative BuyGet Alert
06/01/2023HOTHBuy Now
Hoth Therapeutics
$1.49839.6%EF Hutton
Elemer Piros
→ $14Assumes → BuyGet Alert
04/27/2023HOTHBuy Now
Hoth Therapeutics
$1.49839.6%EF Hutton
Constantine Davides
→ $14Reiterates → BuyGet Alert
04/10/2023HOTHBuy Now
Hoth Therapeutics
$1.49235.57%Benchmark
Bruce Jackson
→ $5Reiterates → Speculative BuyGet Alert
04/03/2023HOTHBuy Now
Hoth Therapeutics
$1.49839.6%EF Hutton
Constantine Davides
$33 → $14MaintainsBuyGet Alert
12/30/2022HOTHBuy Now
Hoth Therapeutics
$1.492114.77%EF Hutton
Constantine Davides
$45 → $33MaintainsBuyGet Alert
03/31/2022HOTHBuy Now
Hoth Therapeutics
$1.4967.79%EF Hutton
Constantine Davides
$68.75 → $62.5MaintainsBuyGet Alert

FAQ

Q

What is the target price for Hoth Therapeutics (HOTH)?

A

The latest price target for Hoth Therapeutics (NASDAQ: HOTH) was reported by HC Wainwright & Co. on February 5, 2024. The analyst firm set a price target for $4.00 expecting HOTH to rise to within 12 months (a possible 168.46% upside). 8 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Hoth Therapeutics (HOTH)?

A

The latest analyst rating for Hoth Therapeutics (NASDAQ: HOTH) was provided by HC Wainwright & Co., and Hoth Therapeutics initiated their buy rating.

Q

When was the last upgrade for Hoth Therapeutics (HOTH)?

A

There is no last upgrade for Hoth Therapeutics.

Q

When was the last downgrade for Hoth Therapeutics (HOTH)?

A

There is no last downgrade for Hoth Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Hoth Therapeutics (HOTH)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Hoth Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Hoth Therapeutics was filed on February 5, 2024 so you should expect the next rating to be made available sometime around February 5, 2025.

Q

Is the Analyst Rating Hoth Therapeutics (HOTH) correct?

A

While ratings are subjective and will change, the latest Hoth Therapeutics (HOTH) rating was a initiated with a price target of $0.00 to $4.00. The current price Hoth Therapeutics (HOTH) is trading at is $1.49, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch